# R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

> **NCT05257018** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 83 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** R-CDOP+intrathecal MTX

## Key facts

- **NCT ID:** NCT05257018
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-26
- **Primary completion:** 2026-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05257018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05257018, "R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05257018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*